Uterine fibroids are the most common benign tumors of the female genitalia and the most common tumors in the human body. It mainly consists of smooth muscle cells proliferating with a small amount of fibrous connective tissue in between. They are most common in women aged 30 to 50 years old, most common in women aged 40 to 50 years old and rare in women under 20 years old. Uterine fibroids are sex hormone-dependent tumors. Estrogen is the main promoter of fibroid growth, and progesterone is the initiating and promoting factor of fibroid development. In addition to surgery, pharmacological treatment is an important measure for fibroid treatment, which is usually considered in combination with the patient’s age, symptoms, size, number, location, fertility requirements and comorbidities. Indications for drug therapy 1.Uterine fibroids less than 2 to 2, 5 months gestational uterus, light symptoms, near menopausal age. 2.Large fibroids that require preservation of reproductive function and avoid excessive incisions. 3.Myomas causing excessive menstruation, anemia, etc. can be considered for surgery, but do not want to operate, women aged 45-50 years old. 4.Larger fibroids are prepared to be removed by cathodic or laparoscopic or hysteroscopic surgery. 5.Women with medical comorbidities who cannot undergo surgery. Contraindications to drug treatment 1.Fibroids grow rapidly and malignant changes cannot be excluded. 2.Uterine fibroids have degenerated and malignant changes cannot be excluded. 3.Symptoms of submembranous fibroids are obvious and affect conception. 4.When the subplasmalemma myoma is twisted. 5.Myoma has caused obvious compression symptoms, or myoma occurred pelvic entrapment can not be reset, etc.